Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review

Sarah R Hoffman, Tam Le, Alexandre Lockhart, Ayodeji Sanusi, Leila Dal Santo, Meagan Davis, Dana A McKinney, Meagan Brown, Charles Poole, Corinne Willame, Jennifer S Smith, Sarah R Hoffman, Tam Le, Alexandre Lockhart, Ayodeji Sanusi, Leila Dal Santo, Meagan Davis, Dana A McKinney, Meagan Brown, Charles Poole, Corinne Willame, Jennifer S Smith

Abstract

A systematic review of the literature was conducted to determine the estimates of and definitions for human papillomavirus (HPV) persistence in women following treatment of cervical intra-epithelial neoplasia (CIN). A total of 45 studies presented data on post-treatment HPV persistence among 6,106 women. Most studies assessed HPV persistence after loop excision (42%), followed by conization (7%), cryotherapy (11%), laser treatment (4%), interferon-alpha, therapeutic vaccination, and photodynamic therapy (2% each) and mixed treatment (38%). Baseline HPV testing was conducted before or at treatment for most studies (96%). Follow-up HPV testing ranged from 1.5 to 80 months after baseline. Median HPV persistence tended to decrease with increasing follow-up time, declining from 27% at 3 months after treatment to 21% at 6 months, 15% at 12 months, and 10% at 24 months. Post-treatment HPV persistence estimates varied widely and were influenced by patient age, HPV-type, detection method, treatment method, and minimum HPV post-treatment testing interval. Loop excision and conization appeared to outperform cryotherapy procedures in terms of their ability to clear HPV infection. This systematic review provides evidence for the substantial heterogeneity in post-treatment HPV DNA testing practices and persistence estimates.

Keywords: CIN; HPV; HPV persistence; cervical cancer; human papillomavirus.

© 2017 UICC.

Figures

Figure 1
Figure 1
Identification and selection of eligible studies.

References

    1. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:123–37. doi: 10.1093/aje/kwn036.
    1. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. doi: 10.1016/S0140-6736(07)61416-0.
    1. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829–46. doi: 10.1097/AOG.0b013e3182883a34.
    1. Jancar N, Rakar S, Poljak M, et al. Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. Eur J Gynaecol Oncol. 2006;27:239–42.
    1. Kreimer AR, Guido RS, Solomon D, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev. 2006;15:908–14.
    1. Tachezy R, Mikysková I, Ludvíková V, et al. Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies. Eur J Clin Microbiol Infect Dis. 2006;25:492–500. doi: 10.1007/s10096-006-0172-5.
    1. Bollen LJ, Tjong-A-Hung SP, van der Velden J, et al. Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol. 1999;72:199–201. doi: 10.1006/gyno.1998.5250.
    1. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802.
    1. Costa S, Venturoli S, Origoni M, et al. Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience. 2015;9:528. doi: 10.3332/ecancer.2015.528.
    1. Cuschieri K, Bhatia R, Cruickshank M, et al. HPV testing in the context of post-treatment follow up (test of cure) J Clin Virol. 2015;76:S56–61. doi: 10.1016/j.jcv.2015.10.008.
    1. Rositch AF, Soeters HM, Offutt-Powell TN, et al. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol. 2014;132:767–79. doi: 10.1016/j.ygyno.2013.12.040.
    1. Aerssens A, Claeys P, Beerens E, et al. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia. Cytopathology. 2009;20:27–35. doi: 10.1111/j.1365-2303.2008.00567.x.
    1. Aerssens A, Claeys P, Garcia A, et al. Natural history and clearance of HPV after treatment of precancerous cervical lesions. Histopathology. 2008;52:381–6. doi: 10.1111/j.1365-2559.2007.02956.x.
    1. Alonso I, Torné A, Puig-Tintoré LM, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol. 2006;103:631–6. doi: 10.1016/j.ygyno.2006.04.016.
    1. Aschkenazi-Steinberg SO, Spitzer BJ, Spitzer M. The role treatment for cervical intraepithelial neoplasia plays in the disappearance of human papilloma virus. J Low Genit Tract Dis. 2005;9:19–22. doi: 10.1097/00128360-200501000-00005.
    1. Bae JH, Kim CJ, Park TC, et al. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer. 2007;17:1271–7. doi: 10.1111/j.1525-1438.2007.00945.x.
    1. Bais AG, Eijkemans MJC, Rebolj M, et al. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. Int J Cancer. 2009;124:889–95. doi: 10.1002/ijc.23824.
    1. Baloglu A, Uysal D, Bezircioglu I, et al. Residual and recurrent disease rates following LEEP treatment in high-grade cervical intraepithelial lesions. Arch Gynecol Obstet. 2010;282:69–73. doi: 10.1007/s00404-009-1298-3.
    1. Bekkers RLM, Melchers WJG, Judith Bakkers MJE, et al. The role of genotype-specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia. Int J Cancer. 2002;102:148–151. doi: 10.1002/ijc.10691.
    1. Bodner K, Bodner-Adler B, Wierrani F, et al. Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? a clinicopathological analysis. Anticancer Res. 2002;22:3733–6.
    1. Bodner K, Bodner-Adler B, Wierrani F, et al. Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: A comparison of preliminary results. Anticancer Res. 2003;23:1785–8.
    1. Bollen LJM, Tjong-A-Hung SP, Velden JVD, et al. Human papillomavirus DNA after treatment of cervical dysplasia: low prevalence in normal cytologic smears. Cancer. 1996;77:2538–43.
    1. Bollen LJ, Tjong-A-Hung SP, van der Velden J, et al. Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia. Sex Transm Dis. 1997;24:456–60.
    1. Branca M, Giorgi C, Ciotti M, et al. Relationship of up-regulation of 67-kd laminin receptor to grade of cervical intraepithelial neoplasia and to high-risk HPV types and prognosis in cervical cancer. Acta Cytol. 2006;50:6–15. doi: 10.1159/000325887.
    1. Brismar S, Johansson B, Borjesson M, et al. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol. 2009;201:17.e1–e8. doi: 10.1016/j.ajog.2009.01.005.
    1. Chumworathayi B, Thinkhamrop J, Blumenthal PD, et al. Cryotherapy for HPV clearance in women with biopsy-confirmed cervical low-grade squamous intraepithelial lesions. Int J Gynecol Obstet. 2010;108:119–22. doi: 10.1016/j.ijgo.2009.09.012.
    1. Cruickshank ME, Sharp L, Chambers G, et al. Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia. Int J Obstet Gynaecol. 2002;109:579–81.
    1. Davidov A, Rajupet SR, Maiman M, et al. LEEP versus cryotherapy: Rates of HPV detection after treatment for CIN II/III. J Low Genit Tract Dis. 2012;16:S7–8.
    1. Debarge VH, Collinet P, Vinatier D, et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol. 2003;90:587–92.
    1. Distéfano AL, Picconi MA, Alonio LV, et al. Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. Infect Dis Obstet Gynecol. 1998;6:214–9. doi: 10.1002/(SICI)1098-0997(1998)6:5 < 214::AID-IDOG5 > ;2-I.
    1. Dogan NU, Salman MC, Yuce K. The role of HPV DNA testing in the follow-up of cervical intraepithelial neoplasia after loop electrosurgical excision procedure. Arch Gynecol Obstet. 2011;283:871–7. doi: 10.1007/s00404-010-1530-1.
    1. Elfgren K, Bistoletti P, Dillner L, et al. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol. 1996;174:937–42. doi: 10.1016/S0002-9378(96)70330-7.
    1. Elfgren K. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia 1, *1. Obstet Gynecol. 2002;100(5):965–71. doi: 10.1016/S0029-7844(02)02280-9.
    1. Fallani MG, Penna C, Marchionni M, et al. Prognostic significance of high-risk HPV persistence after laser CO 2 conization for high-grade CIN: a prospective clinical study. Eur J Gynaecol Oncol. 2008;29:378–382.
    1. Gallwas J, Ditsch N, Hillemanns P, et al. The significance of HPV in the follow-up period after treatment for CIN. Eur J Gynaecol Oncol. 2010;31:27–30.
    1. Gutierrez CMC, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther. 2004;15:421–31.
    1. Heymans J, Benoy IH, Poppe W, et al. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer. 2011;129:903–9. doi: 10.1002/ijc.25745.
    1. Ichimura H, Yamaguchi S, Kojima A, et al. Eradication and reinfection of human papillomavirus after photodynamic therapy for cervical intraepithelial neoplasia. Int J Clin Oncol. 2003;8:322–5. doi: 10.1007/s10147-003-0354-4.
    1. Jones J, Saleem A, Rai N, et al. Human Papillomavirus genotype testing combined with cytology as a “test of cure” post treatment: The importance of a persistent viral infection. J Clin Virol. 2011;52:88–92. doi: 10.1016/j.jcv.2011.06.021.
    1. Kang WD, Oh MJ, Kim SM, et al. Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. Am J Obstet Gynecol. 2010;203:72.e1–e6. doi: 10.1016/j.ajog.2010.01.063.
    1. Kreimer AR, Katki HA, Schiffman M, et al. Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3. Cancer Epidemiol Biomarkers Prev. 2007;16:11–6. doi: 10.1158/1055-9965.EPI-06-0710.
    1. Kreimer AR, Schiffman M, Herrero R, et al. Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int J Cancer. 2012;131:211–8.
    1. Lin CT, Tseng CJ, Lai CH, et al. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am J Obstet Gynecol. 2001;184:940–5. doi: 10.1067/mob.2001.112589.
    1. Mikolajczyk K, Kedzia W, Zaba R, et al. Evaluation of HPV DNA HR assay in females as a marker of recurrent disease following treatment of cervical intraepithelial neoplasia. Ginekol Pol. 2011;82:670–4.
    1. Moore EE, Danielewski JA, Garland SM, et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol. 2011;117:101–8. doi: 10.1097/AOG.0b013e318220efc8.
    1. Nagai N, Mukai K, Oshita T, et al. Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III—a prospective study. Int J Mol Med. 2004;13:589–593.
    1. Nam K, Chung S, Kim J, Jeon S, Bae D. Factors associated with HPV persistence after conization in patients with negative margins. J Gynecol Oncol. 2009:2091–95. doi: 10.3802/jgo.2009.20.2.91.
    1. Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer. 2001;84:796–801. doi: 10.1054/bjoc.2000.1689.
    1. Park JY, Lee KH, Dong SM, et al. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol. 2008;108:549–54. doi: 10.1016/j.ygyno.2007.11.009.
    1. Perrons C, Brink N, Jalal H, et al. The impact of high risk human papillomavirus testing in an Inner London Colposcopy Clinic. J Med Virol. 2005;76:576–82. doi: 10.1002/jmv.20401.
    1. Ribaldone R, Boldorini R, Capuano A, et al. Role of HPV testing in the follow-up of women treated for cervical dysplasia. Arch Gynecol Obstet. 2010;282:193–7. doi: 10.1007/s00404-009-1316-5.
    1. Ryu A, Nam K, Kwak J, et al. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. J Gynecol Oncol. 2012;23:217. doi: 10.3802/jgo.2012.23.4.217.
    1. Sarian LOZ, Derchain SFM, Pitta DDR, et al. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ) J Clin Virol. 2004;31:270–4. doi: 10.1016/j.jcv.2004.05.012.
    1. Sesti F, De Santis L, Farné C, et al. Efficacy of CO2 laser surgery in treating squamous intraepithelial lesions. An analysis of clinical and virologic results. J Reprod Med. 1994;39:441–4.
    1. Theodoropoulos P, Agorastos T, Lambropoulos A, et al. Persistence of human papillomavirus infection after local interferon-alpha treatment of cervical intraepithelial neoplasia. Cervix Low Female Genit Tract. 1994;12:130–2.
    1. Rositch AF, Koshiol J, Hudgens MG, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013;133:1271–85. doi: 10.1002/ijc.27828.
    1. Fambrini M, Penna C, Pieralli A, et al. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2008;109:59–64. doi: 10.1016/j.ygyno.2007.12.032.
    1. Baser E, Ozgu E, Erkilinc S, et al. Risk factors for human papillomavirus persistence among women undergoing cold-knife conization for treatment of high-grade cervical intraepithelial neoplasia. Int J Gynecol Obstet. 2014;125:275–8. doi: 10.1016/j.ijgo.2013.12.012.
    1. Wu J, Jia Y, Luo M, et al. Analysis of residual/recurrent disease and its risk factors after loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia. Gynecol Obstet Invest. 2016;81:296–301. doi: 10.1159/000437423.
    1. Mariani L, Sandri MT, Preti M, et al. HPV-Testing in follow-up of patients treated for CIN2+ lesions. J Cancer. 2016;7:107–14. doi: 10.7150/jca.13503.
    1. van der Heijden E, Lopes AD, Bryant A, et al. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev. 2015;1:CD010757. doi: 10.1002/14651858.CD010757.pub2.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner